![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
12-week raltegravir-intensified quadruple therapy versus triple first-line ART reduces viral load more rapidly but does not reduce mortality in severely immunosuppressed African HIV-infected adults and older children: the REALITY trial
|
|
|
Reported by Jules Levin
Durban 2016 IAS July 18-22
Cissy Kityo, Abraham Siika, Alexander J. Szubert, Jane Mallewa, Mutsa Bwakura-Dangarembizi, Sheila Kabahenda, Shalton Mwaringa, Sarah L. Pett, Anna Griffiths, Abbas Lugemwa, Simon Wachira, Godfrey Musoro, Chatu Rajapakse, Timothy Etyang, James Abach, Priscilla Wavamunno, Linda Nyondo-Mipando, Andrew Reid, Kusum Nathoo, James Hakim, Diana M. Gibb, A. Sarah Walker
and the REALITY trial team
![IAC1](../images/072616/072616-1/IAC1.gif)
![IAC2](../images/072616/072616-1/IAC2.gif)
![IAC3](../images/072616/072616-1/IAC3.gif)
![IAC4](../images/072616/072616-1/IAC4.gif)
![IAC5](../images/072616/072616-1/IAC5.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|